<DOC>
	<DOCNO>NCT02733874</DOCNO>
	<brief_summary>A multi-center , randomize , single blind , positive control trial assess effectiveness , safety cost-effectiveness analysis patient mild moderate psoriasis vulgaris compare Compound Clobetasol Propionate Ointment Calcipotriol Betamethasone Ointment . Objectives Studyï¼š 1 . Compare Compound Clobetasol Propionate Ointment Calcipotriol Betamethasone Ointment treatment mild moderate psoriasis vulgaris effectiveness safety ; 2 . Compare cost-effectiveness analysis two treatment program .</brief_summary>
	<brief_title>A Trial That Compound Clobetasol Propionate Ointment Treats Patients With Mild Moderate Psoriasis Vulgaris .</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Betamethasone benzoate</mesh_term>
	<mesh_term>Betamethasone-17,21-dipropionate</mesh_term>
	<mesh_term>Betamethasone</mesh_term>
	<mesh_term>Betamethasone Valerate</mesh_term>
	<mesh_term>Clobetasol</mesh_term>
	<mesh_term>Betamethasone sodium phosphate</mesh_term>
	<mesh_term>Calcipotriene</mesh_term>
	<criteria>1 . The informed consent sign ; 2 . Patients 18~65 year age , stable psoriasis patient , gender limit ; 3 . The lesion area exceed 10 % total surface area body ; 4 . The overall evaluation researcher ( Physician Global Assessment , PGA ) great equal 2 ; 5 . The observation target lesion minimum diameter great equal 2cm . 1 . Patients know doubted allergic composition drug ; 2 . Patients diagnose nonpsoriasis vulgaris ( erythrodermic type , pustular psoriasis , arthritis ) , develop psoriasis vulgaris ; 3 . Patients illnesses severe central nervous system , cardiovascular system , kidney , liver , digestive tract , respiratory system , metabolism skeletal muscle system mental disorder ; 4 . Patients disease may affect assessment efficacy , eczema , etc . ; 5 . Liver function ( Alanine aminotransferase , Aspartate transaminase ) 2 time great ( equal ) upper limit normal value , renal function ( creatinine ) 1.5 time great ( equal ) upper limit normal value ; 6 . Patients hypercalcemia whose serum calcium value exceed upper limit normal value patient suspect disease hypercalcemia ; 7 . Patients take drug affect metabolism calcium . Drugs increase serum calcium value : agent contain calcium , active vitamin D3 medication , injection , anabolic agent ( ipriflavone preparation ) ; Drugs decrease serum calcium value : calcitonin preparation , double phosphate ester compound preparation , sex hormone preparation ) . 8 . Patients randomly divide group receive systemic biological treatment ( list unlisted ) , : ustekinumab treatment accept patient past 12 week , infliximab , adalimumab treatment accept patient past 8 week , infliximab , etanercept treatment accept patient past 4 week accept ; 9 . Patients accept nonabiotic systemic therapy may effect psoriasis , include limited vitamin A preparation , cortical hormone , vitamin D analog , immunosuppressant , compound glycyrrhizin , traditional Chinese medicine past 4 week random entry test period . 10 . Patients accept psoralen ultraviolet A ( PUVA ) treatment past 4 week random entry test period . 11 . Patients accepted ultraviolet therapy partial treatment psoriasis drug past 2 week random entry test period ; 12 . Patients use concomitant drug recently past 2 week random entry plan use concomitant drug test period , Beta blocker , anti malaria drug , lithium preparation , etc . ; 13 . Patients accept clinical trial last 4 week random entry ; 14 . Patients work outside long time sun exposure may impact diagnosis treatment disease . 15 . Women lactation , pregnancy childbearing age refuse accept effective contraceptive measure . 16 . Patients know suspected noncompliance , alcoholism , drug dependence mental illness , etc , suitable clinical trial judge investigator .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>April 2016</verification_date>
</DOC>